Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pulmotect, Inc.
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
In this month's issue of Start-Up, we profile Flow Forward, Intensity Therapeutics, Perimeter Medical Imaging, PhageTech and Pulmotect.
Summarizing the month in European dealmaking.